药物诱导疾病的临床评估
1Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas 75390-8859, USA. rebecca.gruchalla@email.swmed.edu
Lancet (London, England)
|November 18, 2000
概括
这一评论有助于医生管理报告药物过敏的患者,通过区分真正的过敏反应与非免疫性药物诱导疾病. 它指导在可能的情况下安全地重新引入药物.
科学领域:
- 临床免疫学临床免疫学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 患者经常报告"药物过敏",使处方决定和患者护理复杂化.
- 将真正的过敏药物反应与其他不良药物事件区分开来是临床上具有挑战性的.
研究的目的:
- 为医生提供一个框架来管理疑似药物诱导疾病的患者.
- 区分免疫介导的过敏药物反应和非过敏药物不良事件.
主要方法:
- 关于药物诱导疾病和过敏反应的医学文献的综述.
- 讨论临床评估工具,包括病史,身体发现和实验室测试.
- 关于可疑药物的安全再注射的指导.
主要成果:
- 提供了区分真实过敏药物反应与其他药物诱导疾病的标准.
- 强调彻底的病史和诊断评估的重要性.
- 提供了管理有药物不良反应史的患者的策略.
结论:
- 药物过敏的准确诊断对于安全的处方至关重要.
- 需要进一步研究药物诱导反应的机制,以改善管理.
- 医生可以通过系统地评估报告的药物过敏来改善患者的护理.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


